Treatment & Guidelines
In the PARTNER 3 Trial, TAVI, compared with surgery, resulted in superior clinical outcomes, improved quality of life and faster discharge for sAS patients.1*
46%reduced risk at 1 year in all-cause death, stroke or rehospitalisation (8.5% vs 15.1% for surgery), p=0.0011
1%death or disabling stroke at 1 year (vs 2.9% for surgery), p=0.031
4-dayshorter length of hospital stay (3 vs 7 days for surgery), p<0.001 1
1-, 6- and 12- monthimprovement in health status (compared to surgery)2
* The PARTNER 3 Trial proved SAPIEN 3 TAVI is superior to surgery on the primary endpoint (all-cause death, all stroke or rehospitalisation) and multiple prespecified secondary endpoints in low-risk patients.
See how the PARTNER 3 Trial and the consensus paper may change the AS treatment landscape.
Content relating to Tavi.today is intented for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.